Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Regenxbio (RGNX) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Regenxbio (RGNX) lobbying for?
Summary of Lobbying Data:
– Lobbying firms used: Knight Capitol Consultants, Regenxbio
– General issues they lobbied on: Taxation/Internal Revenue Code, Pharmacy, Health Issues, Immigration, Medicare/Medicaid, Copyright/Patent/Trademark, Trade (domestic/foreign)
– Specific issues they lobbied on: Legislative proposals to reinstate direct expensing of R&D investment, drugs/biologics and orphan drug-related provisions, potential legislation implementing value-based purchasing for pharmaceuticals, retention of 12 years of regulatory data protection for biologics in international trade agreements, PTAB reform bill, development of Value-Based Agreement legislation, proposed Covid-19 IP waivers, IP issues related to the enactment of the drug pricing provisions of the IRA, possible legislation which may affect Food and Drug Administration review of biologic products, reform of Section 101 of the patent code, IP proposals related to drug pricing legislation, Investment and Jobs Act (PL 117-58)
– Government agencies they lobbied: Department of State (DOS), Patent & Trademark Office (PTO), House of Representatives, Department of Justice, Food & Drug Administration (FDA), Department of Health & Human Services (HHS), Senate, Centers For Medicare and Medicaid Services (CMS), Department of Homeland Security (DHS)
One could infer that Regenxbio is lobbying on these issues because they are a biotechnology company and these issues directly affect their business. For example, they are lobbying on legislation related to R&D investment, orphan drug-related provisions, and IP issues related to drug pricing because these issues are critical to the development and marketing of their products. They are also lobbying on issues related to international trade agreements and PTAB reform bill, which may affect their ability to protect their intellectual property. The company is also lobbying on legislative proposals related to healthcare, which affects their ability to bring their products to market and obtain regulatory approval. Finally, they are lobbying various government agencies, including the FDA and HHS, to influence policy decisions that could impact their business operations.
